advancing tremendous over activator have Brian. to X development date PK generated and sickle potential disease clinical development experience, of made years and and and of to industry's program. programs our ongoing derisk with thalassemia cell PK our organization . Led to we function highlights PK and research data in the quality XXXX, .
In most our deficiency, advanced life. the consistent now Thanks, this activator molecule compelling for progress development by, patient continue transform the
first Phase I the Phase III reading out ACTIVATE name the top stabilizer enrollment in our III for Phase compound lower-risk regularly trial pediatric the PK potential milestones, pipeline, for, that completing patients for our the ACTIVATE enrolling for data ITC PK. note for deficiency we study with for of and and in of including We MDS pleased with remain deliver for our PAH transfused the are trial pediatric we line on the study also IIb and to patients AG-XXX, on are growing in enthusiastic the in patients to about rest track AG-XXX Phase the KIT
rate investigators. Turning have to pleased Phase The in was we present II/III observed. an December. study its primary response achieved portion the from sickle of positive crisis of results of ASH pain II disease, been the addition, RISEUP the by hemoglobin to And we endpoint in sickle Phase in study of and cell were improvement delighted detailed Metapiva cell annualized at
of continue study Phase III We year. remain this enrollment end this in the to enrollment of portion advance the on complete to by and track
cell for patients and to potential a to there landscape disease best-in-class unmet treatment disease. gene both the deliver suffering option oral sickle in options novel and cell believe for convenient an evolve, crisis, the and address we in need devastating from this continues urgent that treatment firmly remains While anemia sickle
highlight on a few nontransfusion-dependent the Phase thalassemia. last moment and reported finally, key month take to top we a thalassemia, of program, data III I'll our elements And line positive in
such a as was transfusion populations thalassemia, X of alpha III Phase designed program and encompassing to different placebo-controlled needs. all beta Phase the III across data thalassemia and reminder, As populations randomized deliver thalassemia with trial
alpha first included and that it but populations to thalassemia, enrolled patients different as alpha want who beta enrolled thalassemia trials were to program patients ENERGIZE or relates regularly patients. needs. not transfused clinical transfusion Both is We that highlight with the
there treatments suffer represents As a the including morbidities, are and death. X/X total Brian patients a approximately patients premature no thalassemia, U.S. of These of FDA-approved dependent quality in of which serious for poor thalassemia from rate mentioned, non-transfusion high life, thrombosis
study. We were, therefore, ENERGIZE very positive announce results the pleased to able to be from
As patients a reminder, beta either XXX nontransfusion-dependent enrolled randomized alpha a mitapivat daily. the XXX milligrams X:X total study of twice thalassemia with or placebo or to ENERGIZE
for and the population. the to are patients that of the and rate number and enrollment in as high this the idea this who rollover regularly supports transfused action take of completion speed were unmet enrolled study not people actual to well The as speaks need motivated
The was response average week hemoglobin defined XX concentration week primary compared to in hemoglobin from increase endpoint this study an at of baseline. rate deciliter per as XX least to gram of X
endpoints hemoglobin The changed week and also to this score from concentration, in both change traffic baseline were assessed key secondary of from average average study from baseline in to XX XX.
endpoint, highly patients the patients primary treatment in mitapivat of in response achieving significant X.X% with hemoglobin arm result arm. the XX.X% of statistically the On treatment placebo demonstrated versus a a with
alone. mitapivat novel health beyond across the red mechanism areas mitapivat's this blood action, with hemoglobin mitapivat generated and on data in effects of cell disease study In the line which extended additional of with focuses overall beneficial
in key baseline with endpoints, an change a significant XXX in milligrams fatigue statistically treatment measure resulted score, important average Specifically, both secondary and including patient-reported improvements patients how in feel facet from of function.
our suggesting to covering that placebo, to all a plan primary secondary prespecified favored Importantly, subgroup no the label endpoints, across was subgroup thalassemia compared analyses and driving which all the for supports responsible subtypes. broad file for results, single
This first what is, cell with with we makes for with PKD observed feel in drug hope what deliver be not but that consistent thalassemia able actually with therefore, better, disease as well. patients improves sickle and the we people to to hemoglobin, only patients
of reporting the morbidities. and longer-term markers benefits had they and better longer-term KOLs of the patients benefits potential potential appreciate hemolysis near-term in to clinicians the Complementing and near less the in thalassemia serious of reduce the other term, trial reducing fatigue felt
presenting looking a meeting. data forward very set full We are the much to medical at
Beyond readout confidence us energized have of we itself, the the readout also energized the C. further data excitement energized gives the for of towards the trial
hemolytic a of whether transfusions of not. patient a in irrespective need is is or anemia Thalassemia
of In action not is mechanism of mitapivat on addition, the transfusions. dependent the for need
hemolytic can P. in transfusions the trial We in in have energized waiting in improvement now documented anemia a in see a positive hemolytic via change an hemoglobin, if the energize to demonstrated reduction also be in already with we are improvement anemia
XX-week period units a the baseline. a XX% units more a or week than response compared of reduction cells XX transfusion cell of reduction red As reduction blood reminder, endpoint transfused with or defined X energized consecutive blood greater any as in transfused in equal is to of through primary
of non-transfusion-dependent ways that studies of us demonstrate which the energized energized trial line design variety a transfusion have in metrics in the thalassemia, a includes burden Like transfusion reduction with used. in study meaningfulness other enables to also in the clinical
and and forward prior by static differentiated encompassing option. label regulatory enable study the by in assessment period data living to are of year, of agency a with and feedback and We as a midyear believe thalassemia energized this people the single convenient and access designed end this to FDA look from important will filings learnings a study both incorporating treatment patients plan We dynamic from that readout energized is this seeking a studies oral to disease. the
the very Overall, in now look that, turn continuing of I'm the in R&D proud I this XXXX organization and forward XXXX. by to With progress to made our Cecilia. momentum will over call tremendous
